Skip to main content

Table 4 Outcome variables with detail of cardiac and trauma patients

From: Influence of early antioxidant supplements on clinical evolution and organ function in critically ill cardiac surgery, major trauma, and subarachnoid hemorrhage patients

Variable All Cardiac surgery Trauma
  AOX Placebo AOX Placebo AOX Placebo
Number 200 113 66
Number 102 98 57 56 34 32
Prior renal failure 61 (30.5%) 49 (43.4%)a 10 (15.1%)
  25 36 20 29 6 4
Acute kidney injury 66 (33%) 50 (44.2%)a 13 (19.7%)
  29 (30%) 36 (37%) 21 (37%) 29 (52%)b 7 6
ARF increase of 50 μmol/L 32 (16%) 29 (27.5%)a 3 (15.2%)
  15 (15%) 17 (17% 13 (23% 16 (29%) 2 1
ARF increase of 90 μmol/L 16 (8%) 15 (13.3%)a 1 (1.5%)
  7 (7%) 9 (9%) 6 (11% 9 (16%) 1 0
CVVH 7 (3.5%) 6 (5.3%) 1 (1.5%)
  6 1c,d 5 1 1 0
Persistent renal failure 11 (5.5%) 10 (8.8%) 1 (1.5%)
  4 (4%) 7 (7%) 3 (5%) 7 (13%)e 1 0
Ventilator-free days 26.3 ± 5.5 26.6 ± 5.3 25.2 ± 6.3
  26.1 ± 5.7 26.6 ± 5.2 25.9 ± 6.7 27.3 ± 3.3e 25.5 ± 4.6 24.9 ± 7.7
Infections (patients with) 70 30 30
  36 34 14 16 17 13
Infectious episodes 91 39 39
  45 46 19 20 21 18
Pneumonia episodes 30 16 14
  14 16 7 9 7 7
Length of stay, days       
In the ICU 5.6 ± 5.5 5.2 ± 5.1 6.3 ± 6.5
  5.8 ± 5.4 5.4 ± 5.7 5.8 ± 6.0 4.7 ± 4.0 5.8 ± 4.4 6.8 ± 8.3
In intermediate care 5.0 ± 5.5 3.6 ± 3.5 6.5 ± 7.2
  4.5 ± 4.9 5.5 ± 6.0 3.3 ± 4.2 3.4 ± 4.1 5.9 ± 7.1 7.1 ± 7.4
In the hospital 24 ± 20 19 ± 13 32 ± 22
  23 ± 20 26 ± 20 20 ± 14 19 ± 13 26 ± 19 39 ± 24f
Deaths       
In the ICU 14 (7%) 11 (9.7%) 2 (3%)
  8 5 6 5 2 0g
In hospital 23 (11.5%) 12 (10.6%) 8 (12.1%)
  14 9 8 6 6 2g
At 3 months 25 (12.5%) 16 (14.2%) 8 (12.1%)
  14 11 8 8 6 2g
  1. Data are presented as number (percentage) and mean ± standard deviation. aP < 0.001. bP = 0.109. cP = 0.05. dSee comment in Results section. eP = 0.17. fP = 0.016. gP = 0.16. Superscript a refers to comparison between diagnostic categories. Superscripts b, c, e, f, and g refer to comparison between antioxidant (AOX) and placebo groups. ARF, acute renal failure; CVVH, continuous veno-venous hemofiltration; ICU, intensive care unit.